Loading clinical trials...
Loading clinical trials...
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Carfilzomib
Pomalidomide
+1 more
Locations
9
United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
The John Theurer Cancer Center @ Hackensack UMC
Hackensack, New Jersey, United States
Columbia University
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
November 1, 2011
Primary Completion Date
July 1, 2020
Completion Date
July 1, 2020
Last Updated
August 1, 2022
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06057402
NCT06870760
Lead Sponsor
Criterium, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions